Skip to main content

Table 3 Hazard ratios in developing combined liver function (LF) events for the six common liver chemistries with/without introducing time-dependent covariates in the Cox models

From: Time variation of high-risk groups for liver function deteriorations within fluctuating long-term liver function after hepatic radiotherapy in patients with hepatocellular carcinoma

Model

Covariate

Value

Hazard ratio (95% CI)

P value

ALL6 score + covariates

ALL6 score

0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (cont.)

1.21 (1.16 – 1.27)

 < 0.001*

Age

 ≤ 60, > 60–68, > 68–76, > 76 (cont.)

0.96 (0.83 – 1.11)

0.583

Gender

Female (Male ref.)

1.44 (1.01 – 2.06)

0.046*

PVTT/IVCTT

Positive (Negative ref.)

1.33 (0.93 – 1.91)

0.114

HBV

Positive (Negative ref.)

1.03 (0.73 – 1.45)

0.868

HCV

Positive (Negative ref.)

1.01 (0.67 – 1.52)

0.961

CTV

Per 100 mL (cont.)

0.98 (0.95 – 1.02)

0.376

NLV

Per 100 mL (cont.)

1.00 (0.98 – 1.02)

0.920

NLDmean

Per 1 Gy (cont.)

0.98 (0.95 – 1.00)

0.090

ALL6 score + covariates + time-dependent covariates

ALL6 score

0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (cont.)

1.17 (1.11 – 1.23)

 < 0.001*

Age

 ≤ 60, > 60–68, > 68–76, > 76 (cont.)

0.96 (0.83 – 1.10)

0.543

Gender

Female (Male ref.)

1.00 (0.64 – 1.56)

0.994

PVTT/IVCTT

Positive (Negative ref.)

1.31 (0.93 – 1.85)

0.125

HBV

Positive (Negative ref.)

1.10 (0.79 – 1.54)

0.560

HCV

Positive (Negative ref.)

1.04 (0.69 – 1.56)

0.856

CTV

Per 100 mL (cont.)

0.98 (0.95 – 1.02)

0.375

NLV

Per 100 mL (cont.)

1.00 (0.98 – 1.02)

0.853

NLDmean

Per 1 Gy (cont.)

0.98 (0.95 – 1.01)

0.171

ALL6 score × time

0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (cont.) per 1 month

1.00 (1.00 – 1.01)

0.065

Gender × time

Female (Male ref.) per 1 month

1.04 (1.01 – 1.07)

0.006*

  1. The hazard increases for baseline total LF score increases (ALL6 score) are kept almost constant over time. Women had equivalent initial hazard as men right after radiotherapy but got higher monthly over time
  2. ALL6 bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, international normalized ratio, albumin, PVTT portal vein tumor thrombosis, IVCTT inferior vena cava tumor thrombosis, HBV hepatitis B virus, HCV hepatitis C virus, CTV clinical target volume, NLV normal liver volume, NLDmean normal liver mean dose
  3. *Statistical significance